FFM
KNSA icon

Fairmount Funds Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Fairmount Funds Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,319,688
Closed -$54.4M – 13
2025
Q4 		$54.4M Sell
1,319,688
-453,151
-26% -$18.2M 4.14% 11
2025
Q3 		$68.8M Hold
1,772,839
– – 6.19% 8
2025
Q2 		$49.1M Buy
1,772,839
+670,591
+61% +$17.1M 6.36% 8
2025
Q1 		$24.5M Sell
1,102,248
-1,092,093
-50% -$22.5M 3.8% 11
2024
Q4 		$43.4M Sell
2,194,341
-1,010,500
-32% -$23.1M 4.32% 11
2024
Q3 		$80.1M Hold
3,204,841
– – 6.49% 6
2024
Q2 		$59.8M Hold
3,204,841
– – 6.76% 7
2024
Q1 		$63.2M Buy
3,204,841
+321,620
+11% +$6.28M 6.89% 5
2023
Q4 		$50.6M Buy
2,883,221
+408,660
+17% +$6.72M 5.34% 6
2023
Q3 		$43M Buy
2,474,561
+1,770,102
+251% +$29.8M 5.17% 6
2023
Q2 		$9.92M Buy
+704,459
New +$9.43M 1.4% 15
2020
Q4 		– Sell
-212,746
Closed -$3.26M – 19
2020
Q3 		$3.26M Buy
212,746
+12,621
+6% +$237K 1.38% 16
2020
Q2 		$5.1M Hold
200,125
– – 2.27% 14
2020
Q1 		$3.1M Buy
200,125
+34,807
+21% +$545K 1.88% 14
2019
Q4 		$1.83M Buy
+165,318
New +$1.44M 1.11% 14

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fairmount Funds Management's KNSA Position: Q1 2026 in Review

Fairmount Funds Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 1,319,688 shares — an estimated $54.4M sold.

Fairmount Funds Management first reported a position in KNSA in Q4 2019 and held it in 15 quarters. The position peaked at $80.1M in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Fairmount Funds Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fairmount Funds Management sold 1,319,688 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $54.4M.
  • Fairmount Funds Management first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Fairmount Funds Management's Kiniksa Pharmaceuticals position peaked at $80.1M in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Fairmount Funds Management's 13F filing for Q1 2026, filed 15 May 2026.